Literature DB >> 20518087

Prophylactic uses of integrin CD18-betaA peptide in a murine polymicrobial peritonitis model.

Kwong-Fai Wong1, Jana Wo, David Ho, Ronnie T Poon, José M Casasnovas, John M Luk.   

Abstract

AIM: To evaluate the prophylactic properties of integrin CD18-betaA peptide in a murine model of abdominal polymicrobial peritonitis and sepsis.
METHODS: Bacterial sepsis was induced in Institute of Cancer Research (ICR) mice by cecal ligation and puncture (CLP) surgery. Inflicted mice were then injected with either sterile saline or CD18-betaA peptide intraperitoneally at 2 h after surgery, and were sacrificed at 12 and 24 h after surgery. Blood samples were immediately collected, and analyzed for endotoxin activity and tumor necrosis factor (TNF)-alpha and interleukin (IL)-6. Lungs and liver were studied for CD45+ leukocyte and CD3 mRNA content. Pulmonary expression of intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM) and E-selectin was also determined.
RESULTS: Intraperitoneal injection of CD18-betaA peptide significantly suppressed circulating endotoxin activity (P < 0.01) at 24 h, as well as serum levels of TNF-alpha (P < 0.05 at 12 and 24 h) and IL-6 (P < 0.01 at 12 h, P < 0.05 at 24 h) in CLP-inflicted mice. CD18-betaA peptide also abrogated leukocyte infiltration into liver and lungs as unveiled by reduced CD45+ leukocyte and CD3 mRNA contents. Furthermore, the peptide significantly reduced pulmonary expression of VCAM (P < 0.01 at 12 h, P < 0.001 at 24 h), E-selectin (P < 0.01 at 12 and 24 h), and ICAM-1 (P < 0.01 at 12 h, P < 0.001 at 24 h). These actions of CD18-betaA peptide collectively protected septic mice against lethality (P < 0.01).
CONCLUSION: CD18-betaA peptide is a potent endotoxin antagonist that can protect surgical patients against sepsis-associated lethality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20518087      PMCID: PMC2880778          DOI: 10.3748/wjg.v16.i21.2648

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  Protection from septic shock by neutralization of macrophage migration inhibitory factor.

Authors:  T Calandra; B Echtenacher; D L Roy; J Pugin; C N Metz; L Hültner; D Heumann; D Männel; R Bucala; M P Glauser
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

Review 2.  Novel strategies for the treatment of sepsis.

Authors:  Niels C Riedemann; Ren-Feng Guo; Peter A Ward
Journal:  Nat Med       Date:  2003-05       Impact factor: 53.440

Review 3.  Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned.

Authors:  K Reinhart; W Karzai
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

Review 4.  Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm.

Authors:  T A Springer
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

5.  Epitope mapping of four monoclonal antibodies recognizing the hexose core domain of Salmonella lipopolysaccharide.

Authors:  J M Luk; S M Lind; R S Tsang; A A Lindberg
Journal:  J Biol Chem       Date:  1991-12-05       Impact factor: 5.157

6.  Selective plasma filtration for treatment of fulminant hepatic failure induced by D-galactosamine in a pig model.

Authors:  D W Y Ho; S T Fan; J To; Y H Woo; Z Zhang; C Lau; J Wong
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

7.  Role of LPS/CD14/TLR4-mediated inflammation in necrotizing enterocolitis: pathogenesis and therapeutic implications.

Authors:  Kwong L Chan; Kwong F Wong; John M Luk
Journal:  World J Gastroenterol       Date:  2009-10-14       Impact factor: 5.742

Review 8.  The pathogenesis of sepsis.

Authors:  R C Bone
Journal:  Ann Intern Med       Date:  1991-09-15       Impact factor: 25.391

9.  Therapeutic effects of lysophosphatidylcholine in experimental sepsis.

Authors:  Ji-Jing Yan; Jun-Sub Jung; Jung-Eun Lee; Jongho Lee; Sung-Oh Huh; Hee-Sung Kim; Kyeong Cheon Jung; Jae-Young Cho; Ju-Suk Nam; Hong-Won Suh; Yung-Hi Kim; Dong-Keun Song
Journal:  Nat Med       Date:  2004-01-11       Impact factor: 53.440

10.  Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide.

Authors:  H S Warren; S F Amato; C Fitting; K M Black; P M Loiselle; M S Pasternack; J M Cavaillon
Journal:  J Exp Med       Date:  1993-01-01       Impact factor: 14.307

View more
  2 in total

1.  Gram-Negative Pneumonia Alters Large-Vein Cell-Adhesion Molecule Profile and Potentiates Experimental Stasis Venous Thrombosis.

Authors:  Andrea T Obi; Elizabeth Andraska; Yogendra Kanthi; Catherine E Luke; Megan Elfline; Suresh Madathilparambil; Teruna J Siahaan; Farouc A Jaffer; Thomas W Wakefield; Krishnan Raghavendran; Peter K Henke
Journal:  J Vasc Res       Date:  2016-10-22       Impact factor: 1.934

2.  Human severe sepsis cytokine mixture increases β2-integrin-dependent polymorphonuclear leukocyte adhesion to cerebral microvascular endothelial cells in vitro.

Authors:  Chris Blom; Brittany L Deller; Douglas D Fraser; Eric K Patterson; Claudio M Martin; Bryan Young; Patricia C Liaw; Payam Yazdan-Ashoori; Angelica Ortiz; Brian Webb; Greg Kilmer; David E Carter; Gediminas Cepinskas
Journal:  Crit Care       Date:  2015-04-07       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.